A Washington University drug discovery program, led by Michael Holtzman, MD, has received three grants totaling more than $5 million to develop new medical therapeutics for respiratory diseases. The target illnesses range from the common cold to life-threatening lung disease.
The School of Medicine has been awarded a career-development grant to support junior faculty members interested in using “omics” technologies to diagnose, treat and prevent lung diseases. The grant, funded by the National Institutes of Health, will help train young pulmonary scientists to apply new analytic omics tools to the study of lung diseases.
Two faculty members from Washington University in St. Louis have been named fellows of the American Association for the Advancement of Science, the world’s largest general scientific society. They are Michael J. Holtzman, MD (left), and Rohit V. Pappu, PhD.